3.4.22.53 (2S)-3-phenyl-2-([[(2S)-1-(phenylsulfonyl)pyrrolidin-2-yl]carbonyl]amino)propanoic acid - 81305 3.4.22.53 (2S)-4-methyl-2-[(phenylsulfonyl)amino]pentanoic acid - 81303 3.4.22.53 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester - 81291 3.4.22.53 110 kDa calpastatin - 81306 3.4.22.53 70 kDa calpastatin - 81307 3.4.22.53 Ac-Thr-Pro-Leu-alpha-azaglycine-Ser-Pro-Pro-NH2 - 201840 3.4.22.53 Ac-Thr-Pro-Leu-alpha-azaglycine-Ser-Pro-Pro-Pro-Ser-NH2 - 201839 3.4.22.53 Ac-Thr-Pro-Leu-alpha-azaglycine-Ser-Pro-Pro-Pro-Ser-Pro-Arg-NH2 - 201838 3.4.22.53 Ac-Thr-Ser-Leu-alpha-azaglycine-Ser-Pro-Pro-Pro-Ser-NH2 - 201842 3.4.22.53 Ac-Thr-Trp-Leu-alpha-azaglycine-Ser-Pro-Pro-Pro-Ser-NH2 - 201841 3.4.22.53 acetyl-Leu-Leu-Nle-CHO - 10273 3.4.22.53 ALLM - 40418 3.4.22.53 ALLN - 25515 3.4.22.53 antipain - 520 3.4.22.53 benzyloxycarbonyl-L-leucyl-L-leucinal - 81302 3.4.22.53 benzyloxycarbonyl-Leu-Leu-leucinal - 113056 3.4.22.53 benzyloxycarbonyl-Leu-Leu-phenylalaninal - 111974 3.4.22.53 benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone - 113057 3.4.22.53 benzyloxycarbonyl-Leu-norleucinal - 113058 3.4.22.53 benzyloxycarbonyl-LLY-fluoromethylketone - 81308 3.4.22.53 calpastatin - 1386 3.4.22.53 calpastatin II - 167879 3.4.22.53 calpeptin - 2399 3.4.22.53 caplastatin 2 - 113171 3.4.22.53 Cbz-Leu-DL-Abu-CONH-(CH2)3-(4-methylpiperazin-1-yl) - 86582 3.4.22.53 Cbz-Leu-DL-Abu-CONH-(CH2)3-2-methoxyadenin-9-yl - 86578 3.4.22.53 Cbz-Leu-DL-Abu-CONH-(CH2)3-adenin-9-yl - 86576 3.4.22.53 Cbz-Leu-DL-Abu-CONH-(CH2)3-cytosin-3-yl - 86580 3.4.22.53 Cbz-Leu-DL-Abu-CONH-(CH2)3-morpholine - 86575 3.4.22.53 CBZ-Leu-DL-Phe-CONH-(CH2)2-N-(CH3)2 - 86585 3.4.22.53 CBZ-Leu-DL-Phe-CONH-(CH2)3-(4-methylpiperazin-1-yl) - 86583 3.4.22.53 CBZ-Leu-DL-Phe-CONH-(CH2)3-2-methoxyadenin-9-yl - 86579 3.4.22.53 CBZ-Leu-DL-Phe-CONH-(CH2)3-cytosin-3-yl - 86581 3.4.22.53 CBZ-Leu-DL-Phe-CONH-(CH2)3-N-(CH3)2 - 86584 3.4.22.53 E-64 - 559 3.4.22.53 EGTA - 173 3.4.22.53 ethyl N-(phenylsulfonyl)-L-leucyl-L-phenylalaninate - 81304 3.4.22.53 indomethacin - 546 3.4.22.53 leupeptin - 217 3.4.22.53 MDL-28170 - 11631 3.4.22.53 MDL28170 - 8857 3.4.22.53 N-acetyl-L-leucyl-L-leucyl-L-methioninal - 160150 3.4.22.53 N-acetyl-Leu-Leu-Met - 160151 3.4.22.53 NS-398 - 5807 3.4.22.53 PD150606 - 7903 3.4.22.53 SC-560 - 18639 3.4.22.53 SNJ-1945 - 40417 3.4.22.53 Thr-Pro-Leu-alpha-azaglycine-Ser-Pro-Pro-Pro-Ser-Pro-Arg-NH2 - 201837 3.4.22.53 Ep-475 0.001 mM, 49% inhibition of the enzyme from retina, 46% inhibition of the enzyme from brain 8103 3.4.22.53 leupeptin 0.001 mM, 67% inhibition of enzyme from retina and brain 217 3.4.22.53 protease inhibitor 0.002 mg/ml, 6% inhibition 51889 3.4.22.53 calpain inhibitor II 0.002 mM, 67% loss of activity 16348 3.4.22.53 calpain inhibitor I 0.002 mM, 90% loss of activity 12965 3.4.22.53 calpain inhibitor II 0.002 mM, 93% loss of activity 16348 3.4.22.53 leupeptin 0.002 mM, 93% loss of activity 217 3.4.22.53 calpain inhibitor I 0.002 mM, 95% loss of activity 12965 3.4.22.53 leupeptin 0.002 mM, complete loss of activity 217 3.4.22.53 antipain 0.01 mM 56% inhibition 520 3.4.22.53 leupeptin 0.01 mM 85% inhibition 217 3.4.22.53 E-64 0.01 mM 89% inhibition 559 3.4.22.53 (2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester 0.01 mM, 50% inhibition 33021 3.4.22.53 antipain 0.01 mM, 80-90% inhibition 520 3.4.22.53 E-64c 0.01 mM, 80-90% inhibition 13400 3.4.22.53 leupeptin 0.01 mM, 80-90% inhibition 217 3.4.22.53 E-64 0.01 mM, 98% inhibition 559 3.4.22.53 pepstatin 0.01 mM, 99% inhibition 396 3.4.22.53 antipain 0.02 mM, 82% loss of activity 520 3.4.22.53 antipain 0.02 mM, 87% loss of activity 520 3.4.22.53 alpha2-Macroglobulin 0.05 mg/ml, 11% inhibition 1068 3.4.22.53 E-64 0.05 mg/ml, complete inhibition 559 3.4.22.53 leupeptin 0.05 mg/ml, complete inhibition 217 3.4.22.53 3,4-dichloroisocoumarin 0.05 mM, 11% inhibition 1040 3.4.22.53 calpain inhibitor I 0.05 mM, 99% inhibition 12965 3.4.22.53 leupeptin 0.05 mM, 99% inhibition 217 3.4.22.53 antipain 0.05 mM, complete inhibition 520 3.4.22.53 calpain inhibitor II 0.05 mM, complete inhibition 16348 3.4.22.53 TLCK 0.1 mM, 60-80% inhibition 4621 3.4.22.53 iodoacetic acid 0.1 mM, 99% inhibition 213 3.4.22.53 N-tosyl-Lys-chloromethyl ketone 0.5 mM, 69% inhibition 113978 3.4.22.53 N-tosyl-Phe-chloromethyl ketone 0.5 mM, 91% inhibition 112048 3.4.22.53 PCMB 1 mM, 42% inhibition 78 3.4.22.53 PCMB 1 mM, 56% inhibition 78 3.4.22.53 PMSF 1 mM, 6% inhibition 248 3.4.22.53 pepstatin A 1 mM, 60-80% inhibition 309 3.4.22.53 iodoacetamide 1 mM, 64% inhibition 67 3.4.22.53 iodoacetic acid 1 mM, 76% inhibition 213 3.4.22.53 NEM 1 mM, 93% inhibition 89 3.4.22.53 iodoacetic acid 1 mM, 99% loss of activity 213 3.4.22.53 iodoacetic acid 1 mM, complete loss of activity 213 3.4.22.53 Fe3+ 2.5 mM, complete 70 3.4.22.53 Hg2+ 2.5 mM, complete 33 3.4.22.53 Ni2+ 2.5 mM, complete 38 3.4.22.53 Zn2+ 2.5 mM, complete 14 3.4.22.53 Co2+ 2.5 mM, strong 23 3.4.22.53 Fe2+ 2.5 mM, strong 25 3.4.22.53 Mn2+ 2.5 mM, strong 11 3.4.22.53 NEM 3.0 mM, high inhibition of activity in presence or absence of Ca2+ 89 3.4.22.53 Cd2+ 5 mM 52 3.4.22.53 Co2+ 5 mM 23 3.4.22.53 Cu2+ 5 mM 19 3.4.22.53 Fe2+ 5 mM 25 3.4.22.53 Fe3+ 5 mM 70 3.4.22.53 Hg2+ 5 mM 33 3.4.22.53 Ni2+ 5 mM 38 3.4.22.53 Zn2+ 5 mM 14 3.4.22.53 4-[[(3,4-dinitrophenyl)carbonyl]amino]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid 5 mM, 23% inhibition 142923 3.4.22.53 PCMB 5 mM, 24% inhibition 78 3.4.22.53 EDTA 5 mM, complete inhibition 21 3.4.22.53 NEM 5 mM, complete inhibition 89 3.4.22.53 Cd2+ 5 mM, completely blocks activation of the enzyme by Ca2+ 52 3.4.22.53 Co2+ 5 mM, completely blocks activation of the enzyme by Ca2+ 23 3.4.22.53 Cu2+ 5 mM, completely blocks activation of the enzyme by Ca2+ 19 3.4.22.53 Ni2+ 5 mM, completely blocks activation of the enzyme by Ca2+ 38 3.4.22.53 Zn2+ 5 mM, completely blocks activation of the enzyme by Ca2+ 14 3.4.22.53 Cd2+ 5 mM, inhibits in presence of 5 mM Ca2+ 52 3.4.22.53 Co2+ 5 mM, inhibits in presence of 5 mM Ca2+ 23 3.4.22.53 Cu2+ 5 mM, inhibits in presence of 5 mM Ca2+ 19 3.4.22.53 Fe2+ 5 mM, inhibits in presence of 5 mM Ca2+ 25 3.4.22.53 Hg2+ 5 mM, inhibits in presence of 5 mM Ca2+ 33 3.4.22.53 K+ 5 mM, inhibits in presence of 5 mM Ca2+ 39 3.4.22.53 Mg2+ 5 mM, inhibits in presence of 5 mM Ca2+ 6 3.4.22.53 Na+ 5 mM, inhibits in presence of 5 mM Ca2+ 59 3.4.22.53 Ni2+ 5 mM, inhibits in presence of 5 mM Ca2+ 38 3.4.22.53 Zn2+ 5 mM, inhibits in presence of 5 mM Ca2+ 14 3.4.22.53 calpeptin 50% inhibition of maximal caseinolytic activity at 10 nM and 21 nM for retinal and brain calpain 2399 3.4.22.53 GAP-43-3 a GAP-43 fragment, lacking about 40 N-terminal residues (named GAP-43-3), is produced by m-calpain-mediated cleavage of GAP-43. The fragment prevents complete cleavage of intact GAP-43 by m-calpain as a negative feedback. GAP-43-3 also blocks m-calpain activity against casein 37835 3.4.22.53 CBZ-Leu-DL-Phe-CONH-(CH2)3-adenin-9-yl best inhibitor 86577 3.4.22.53 acetyl-Leu-Leu-Nle-CHO broad spectrum calpain inhibitor 10273 3.4.22.53 benzyloxycarbonyl-Leu-Abu-CONH-CH2-C6H3(3,5-(OMe)2) calpain-2 selective inhibitor. A selective calpain-2 inhibitor could prevent acute glaucoma-induced retinal ganglion cell death and blindness 239887 3.4.22.53 Calmidazolium calpain-specific inhibitor 3621 3.4.22.53 acetyl-Leu-Leu-Nle-CHO complete inhibition at 0.001 mM 10273 3.4.22.53 calpeptin complete inhibition at 0.001 mM 2399 3.4.22.53 EDTA completely inactivated by 4 mM EDTA plus 4 mM EGTA 21 3.4.22.53 EGTA completely inactivated by 4 mM EDTA plus 4 mM EGTA 173 3.4.22.53 calpastatin endogenous inhibitor 1386 3.4.22.53 calpastatin endogenous inhibitor of calpain 1386 3.4.22.53 Z-Val-Phe-CHO i.e. MDL-28710m, 1.0 microM 63135 3.4.22.53 E-64 i.e. trans-epoxysuccinyl-L-leucylamido-(4-guanido)butane 559 3.4.22.53 Al3+ inactivation at millimolar concentration of Ca2+ 264 3.4.22.53 calpastatin inhibition of m-calpain is greater at pH 7.5 than at pH 6.5 at both 165 mM and 295 mM NaCl. Percentage inhibition is greater at 295 mM than at 165 mM NaCl 1386 3.4.22.53 K+ inhibits at high concentrations 39 3.4.22.53 Na+ inhibits at high concentrations 59 3.4.22.53 Ca2+ initiation of autolysis of calpain 2 by adding of 1 mM CaCl2 15 3.4.22.53 NaCl m-calpain is more active at 165 mM NaCl than at 295 mM NaCl 42 3.4.22.53 additional information not inhibited by Ac-Thr-Pro-Leu-alpha-azaglycine-Ser-Pro-NH2, Ac-Pro-Leu-alpha-azaglycine-Ser-Pro-Pro-Pro-Ser-NH2, Ac-Leu-alpha-azaglycine-Ser-Pro-Pro-Pro-Ser-NH2, Ac-alpha-azaglycine-Ser-Pro-Pro-Pro-Ser-NH2, Ac-Thr-Pro-Thr-alpha-azaglycine-Ser-Pro-Pro-Pro-Ser-NH2, Ac-Thr-Pro-Leu-alpha-azaglycine-Ser-Ser-Pro-Pro-Ser-NH2, Ac-Thr-Pro-Leu-alpha-azaglycine-Ser-Gln-Pro-Pro-Ser-NH2, Ac-Thr-Pro-Val-alpha-azaglycine-Ser-Pro-Pro-Pro-Ser-NH2, Ac-Thr-Pro-Leu-alpha-azaglycine-Thr-Pro-Pro-Pro-Ser-NH2, and Ac-Thr-Pro-Leu-alpha-azaglycine-Arg-Pro-Pro-Pro-Ser-NH2 2 3.4.22.53 additional information not inhibited by benzyloxycarbonyl-VAD-fluoromethylketone 2 3.4.22.53 calpastatin oxidation lowers calpastatin inhibition of m-calpain at al pH and ionic strength combinations 1386 3.4.22.53 Polyethylene glycol PEG-4000, PEG-100000 or PEG-20000, inhibition at concentrations higher than 0.5% 2868 3.4.22.53 MDL28170 selective calpain inhibitor 8857 3.4.22.53 acetyl-Leu-Leu-Met-CHO selectively inhibits the activity of calpain-2 81290 3.4.22.53 additional information specific capn2 shRNA reduces expression of the targeted isoform 2 3.4.22.53 calpastatin specific competitive inhibitor 1386 3.4.22.53 calpastatin specific inhibitor 1386 3.4.22.53 additional information suppression of calpain-2 expression with adenovirus vector-mediated RNAi 2 3.4.22.53 calpeptin Z-Leu-Nle-CHO 2399